Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12,638 Mln
P/E Ratio
--
P/B Ratio
46.29
Industry P/E
--
Debt to Equity
0.16
ROE
-8.91 %
ROCE
-151.92 %
Div. Yield
0 %
Book Value
1.59
EPS
-5.1
CFO
$-2,499.40 Mln
EBITDA
$-2,868.26 Mln
Net Profit
$-3,104.72 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Insmed Inc (INSM)
| 2.55 | -11.41 | -9.75 | 193.65 | 45.87 | 28.14 | 11.84 |
|
BSE Sensex*
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Midcap 400
| -10.62 | -5.43 | -15.03 | -2.69 | 2.55 | 12.99 | 6.16 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Insmed Inc (INSM)
| 121.33 | 55.11 | -26.65 | -18.17 | 39.41 | 82.01 | -57.72 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 241.97 | 30,358.28 | -- | 362.29 | |
| 131.87 | 14,047.06 | -- | -8.58 | |
| 147.06 | 24,899.21 | 18.88 | 22.55 | |
| 33.23 | 18,604.29 | -- | -94.9 |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial... lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. Address: 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 Read more
President, CEO & Chairman
Mr. William H. Lewis J.D., M.B.A.
President, CEO & Chairman
Mr. William H. Lewis J.D., M.B.A.
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Insmed Inc (INSM) stood at $ 2,025 Mln as on 31-Dec-24
The share price of Insmed Inc (INSM) is $70.80 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Insmed Inc (INSM) has given a return of 45.87% in the last 3 years.
Insmed Inc (INSM) has a market capitalisation of $ 12,638 Mln as on 22-Apr-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Insmed Inc (INSM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Insmed Inc (INSM) and enter the required number of quantities and click on buy to purchase the shares of Insmed Inc (INSM).
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. Address: 700 US Highway 202/206, Bridgewater, NJ, United States, 08807
The CEO & director of Mr. William H. Lewis J.D., M.B.A.. is Insmed Inc (INSM), and CFO & Sr. VP is Mr. William H. Lewis J.D., M.B.A..
There is no promoter pledging in Insmed Inc (INSM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
2,983
|
|
|
2,617
|
|
|
1,700
|
|
|
1,405
|
| Insmed Inc (INSM) | Ratios |
|---|---|
|
Return on equity(%)
|
3926.49
|
|
Operating margin(%)
|
-228.15
|
|
Net Margin(%)
|
-251.24
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Insmed Inc (INSM) was $0 Mln.
$-0.44
(
